Cancers最新文献

筛选
英文 中文
Older Age Does Not Predict Inadequate Pain Management in Cancer Patients: A Multicenter Prospective Analysis from Italian Radiotherapy Departments (ARISE-Study). 老年不能预测癌症患者疼痛管理不足:来自意大利放疗部门的多中心前瞻性分析(rise -研究)。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183073
Costanza M Donati, Erika Galietta, Francesco Cellini, Arina A Zamfir, Alessia Di Rito, Maurizio Portaluri, Anna Santacaterina, Filippo Mammini, Rossella Di Franco, Salvatore Parisi, Antonella Bianculli, Pierpaolo Ziccarelli, Luigi Ziccarelli, Domenico Genovesi, Luciana Caravatta, Francesco Deodato, Gabriella Macchia, Francesco Fiorica, Silvia Cammelli, Milly Buwenge, Lucia Angelini, Romina Rossi, Marco C Maltoni, Nam P Nguyen, Alessio G Morganti, Savino Cilla
{"title":"Older Age Does Not Predict Inadequate Pain Management in Cancer Patients: A Multicenter Prospective Analysis from Italian Radiotherapy Departments (ARISE-Study).","authors":"Costanza M Donati, Erika Galietta, Francesco Cellini, Arina A Zamfir, Alessia Di Rito, Maurizio Portaluri, Anna Santacaterina, Filippo Mammini, Rossella Di Franco, Salvatore Parisi, Antonella Bianculli, Pierpaolo Ziccarelli, Luigi Ziccarelli, Domenico Genovesi, Luciana Caravatta, Francesco Deodato, Gabriella Macchia, Francesco Fiorica, Silvia Cammelli, Milly Buwenge, Lucia Angelini, Romina Rossi, Marco C Maltoni, Nam P Nguyen, Alessio G Morganti, Savino Cilla","doi":"10.3390/cancers17183073","DOIUrl":"10.3390/cancers17183073","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have often reported a link between advanced age and inadequate cancer pain management. Given Italy's demographic profile as the country with the oldest population in Europe, it offers an ideal setting to explore whether this association remains valid today.</p><p><strong>Aim: </strong>This study aimed primarily to assess the influence of advanced age on the adequacy of pain management among patients receiving treatment in Italian radiotherapy (RT) departments, and secondarily, to identify age-specific determinants of analgesic undertreatment.</p><p><strong>Methods: </strong>In this prospective, multicenter study, we enrolled 2104 consecutive patients attending 13 RT centers between October and November 2019. Pain intensity was evaluated using the numeric rating scale (NRS), and patients reporting scores ≥ 1 (<i>n</i> = 1353) were included in the analysis. Pain management adequacy was assessed using the Pain Management Index (PMI), with negative values indicating undertreatment. A two-step statistical approach was employed: variable selection via Least Absolute Shrinkage and Selection Operator regression, followed by Classification and Regression Tree analysis to identify key predictors. Separate analyses were performed for the overall population, older adults (≥65 years), and younger adults (18-64 years).</p><p><strong>Results: </strong>Overall, 42% of patients were undertreated (PMI < 0), without significant differences between older (41.0%) and younger patients (43.1%). However, factors contributing to undertreatment varied according to age. For the entire cohort, non-cancer pain was associated with substantially higher rates of undertreatment (74.3%) compared to cancer-related pain (34.2%). Among cancer patients, those receiving curative RT had poorer pain control (49.4%) than those receiving palliative RT (28.8%). In older patients, geographic location strongly influenced pain management, with higher rates of undertreatment in central and southern Italy compared to the north (e.g., palliative RT: 64.0% vs. 15.4%, respectively). Conversely, younger patients showed no geographical differences; instead, timing of assessment (beginning vs. end of RT) influenced outcomes, with improved PMI values towards the end of treatment.</p><p><strong>Conclusions: </strong>Unlike previous studies, advanced age itself was not associated with inadequate analgesia. However, the determinants of inadequate pain management differed significantly by age: geographic disparities were predominant among older patients, while assessment timing influenced outcomes for younger patients. Further longitudinal research and targeted interventions are needed to address these age-dependent challenges.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145173994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Melanoma Clues Beyond Dermoscopic Patterns: Lesion Orientation to Langer's Lines as a Predictor on the Trunk. 皮肤镜模式之外的黑色素瘤线索:兰格线的病变方向作为主干上的预测因子。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183064
Umberto Santaniello, Francesco Cavallo, Sara Diana, Silvia Giordano, Orsola Crespi, François Rosset, Andrea Agostini, Giovenale Moirano, Paolo Fava, Pietro Quaglino, Simone Ribero, Paolo Broganelli
{"title":"Melanoma Clues Beyond Dermoscopic Patterns: Lesion Orientation to Langer's Lines as a Predictor on the Trunk.","authors":"Umberto Santaniello, Francesco Cavallo, Sara Diana, Silvia Giordano, Orsola Crespi, François Rosset, Andrea Agostini, Giovenale Moirano, Paolo Fava, Pietro Quaglino, Simone Ribero, Paolo Broganelli","doi":"10.3390/cancers17183064","DOIUrl":"10.3390/cancers17183064","url":null,"abstract":"<p><strong>Background/objectives: </strong>The diagnosis of melanocytic lesions on the trunk is challenging due to a high frequency of atypical features in benign nevi, leading to a high rate of unnecessary excisions. This study aimed to identify robust dermoscopic predictors of cutaneous melanoma on the trunk and to evaluate a novel diagnostic criterion: the orientation of lesions relative to Langer's skin tension lines.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 321 melanocytic lesions (227 nevi and 94 melanomas) excised from the trunk. Dermoscopic features were systematically evaluated. A chi-square test and an age- and sex-adjusted multivariate logistic regression were performed to calculate odds ratios (OR) and identify independent predictors of malignancy. A subgroup analysis was also conducted on \"critical\" versus \"non-critical\" anatomical sites.</p><p><strong>Results: </strong>Non-adherence to Langer's lines was the most powerful predictor of melanoma (OR 5.55, 95% CI 3.22-9.81; <i>p</i> < 0.001). Other significant predictors included blue-white veil (OR 5.09) and polymorphous vessels (OR 4.06). Notably, 70% of melanomas did not align with Langer's lines, whereas 72% of nevi did. Classic features such as scar-like regression were not statistically significant predictors in this cohort. In the subgroup analysis, color asymmetry was a significant predictor of melanoma only in non-critical sites (p for interaction = 0.026).</p><p><strong>Conclusions: </strong>The orientation of a melanocytic lesion relative to Langer's lines is a powerful and independent predictor of melanoma on the trunk. This simple morphological feature, which may reflect differences in growth patterns between malignant and benign lesions, could serve as an additional clinical cue to support decision-making and improve diagnostic accuracy in this challenging anatomical location.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145173874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Utility of T2-Weighted MRI Radiomics in the Prediction of Post-Exenteration Disease Recurrence: A Multi-Centre Externally Validated Study via the PelvEx Collaborative. t2加权MRI放射组学在预测拔牙后疾病复发中的应用:一项通过PelvEx协作的多中心外部验证研究。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183061
PelvEx Collaborative
{"title":"The Utility of T2-Weighted MRI Radiomics in the Prediction of Post-Exenteration Disease Recurrence: A Multi-Centre Externally Validated Study via the PelvEx Collaborative.","authors":"PelvEx Collaborative","doi":"10.3390/cancers17183061","DOIUrl":"10.3390/cancers17183061","url":null,"abstract":"<p><p><b>Introduction:</b> Recurrence after pelvic exenteration remains a significant concern in patients with locally advanced rectal cancer (LARC). Therefore, there is a need for improved non-invasive predictive tools to aid in patient selection. Radiomics, which extracts quantitative imaging features, may help identify patients at greater risk of recurrence. This study aimed to develop and validate a radiomics-based nomogram using pre-treatment MRI to predict postoperative recurrence risk in LARC. <b>Methods:</b> The largest multicenter retrospective radiomics analysis of 191 patients with pathologically confirmed LARC treated at fourteen centres (2016-2018) was performed. All patients received neoadjuvant chemoradiotherapy followed by curative-intent exenterative surgery. Manual tumour segmentation was performed on pre-treatment T2-weighted MRI. Feature selection employed LASSO regression with 5-fold cross-validation across 1000 bootstrap samples. The most frequently selected features were used to construct a logistic regression model via stepwise backward selection. Model performance was assessed using ROC analysis, calibration plots, decision curve analysis, and internal validation with 1000 bootstraps. A nomogram was generated to enable individualized recurrence risk estimation. <b>Results:</b> Postoperative recurrence occurred in 51% (<i>n</i> = 98) of cases. Five radiomic features reflecting tumour heterogeneity, morphology, and texture were included in the final model. In multivariable analysis, all selected features were significantly associated with recurrence, with odds ratios ranging from 0.63 to 1.64. The model achieved an optimism-adjusted AUC of 0.70, indicating fair discrimination. Calibration plots showed good agreement between predicted and observed recurrence probabilities. Decision curve analysis confirmed clinical utility across relevant thresholds. A clinically interpretable nomogram was developed based on the final model. <b>Conclusions:</b> A radiomics-based model using preoperative MRI can predict recurrence in LARC. The derived nomogram provides a practical tool for preoperative risk assessment. Prospective validation is necessary.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan. 接受曲妥珠单抗的her2阳性转移性乳腺癌患者体内成分变化对治疗相关毒性和临床结果的影响
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183063
Alessio Molfino, Giovanni Imbimbo, Simona Pisegna, Simone Scagnoli, Claudia Alabiso, Massimiliano Ardovino, Carmen Gallicchio, Veronica Rizzo, Andrea Botticelli
{"title":"Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan.","authors":"Alessio Molfino, Giovanni Imbimbo, Simona Pisegna, Simone Scagnoli, Claudia Alabiso, Massimiliano Ardovino, Carmen Gallicchio, Veronica Rizzo, Andrea Botticelli","doi":"10.3390/cancers17183063","DOIUrl":"10.3390/cancers17183063","url":null,"abstract":"<p><strong>Background/objectives: </strong>Breast cancer remains a significant global health concern, with HER2-positive metastatic breast cancer continuing to present persistent challenges despite advancements in targeted therapies, including trastuzumab deruxtecan (T-DXd). This study aimed to verify the impact of body composition changes on treatment-related toxicities, dose modifications, and clinical outcomes in patients receiving T-DXd.</p><p><strong>Methods: </strong>A retrospective analysis on 35 patients with HER2-positive metastatic breast cancer was conducted, analyzing body composition parameters such as subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), skeletal muscle area (SMA), and skeletal muscle index (SMI)-assessed using CT scans at baseline (T0) and after a median follow-up of 4 months (T1)-and calculating ΔT0-T1% of each parameter.</p><p><strong>Results: </strong>Significant reductions over time were observed in SAT (mean ΔSAT% = -5.7%, <i>p</i> = 0.023) and SMA (mean ΔSMA% = -4.9%, <i>p</i> = 0.001). Treatment-related adverse events (AEs) were common, with 31% of patients experiencing severe (Grade 3-4) toxicities. Patients with higher ΔSAT% (above the median value) experienced Grade 3-4 toxicities more frequently compared to those with lower ΔSAT% (below the median) (<i>p</i> < 0.05). Among patients without toxicities, a significant decrease in SAT was observed between T0 and T1 (<i>p</i> = 0.003), while no significant change was detected in patients with Grade 3-4 toxicities (<i>p</i> = 0.929). Greater reductions in SMA were associated with increased rates of treatment discontinuation (75% vs. 29%, <i>p</i> = 0.009). Kaplan-Meier analysis confirmed that greater reductions in SMA significantly increased the risk of mortality (HR 5.1, 95% CI: 1.05-24.79; <i>p</i> = 0.025) and showed a trend toward higher risk of disease progression (HR 2.58, 95% CI: 0.89-7.49; <i>p</i> = 0.063).</p><p><strong>Conclusions: </strong>Changes in body composition, particularly reductions in SMA, were associated with increased treatment discontinuation and mortality in HER2-positive metastatic breast cancer receiving T-DXd. Increase in SAT was associated with higher rates of severe toxicities, highlighting its potential role in predicting treatment-related complications, and the clinical relevance of nutritional changes on outcomes in this setting.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145173726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brainstem Glioma Prognostication: Static FET PET/CT. 脑干胶质瘤预测:静态FET PET/CT。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183065
Dávid Gergő Nagy, Júlia Singer, Katalin Borbély
{"title":"Brainstem Glioma Prognostication: Static FET PET/CT.","authors":"Dávid Gergő Nagy, Júlia Singer, Katalin Borbély","doi":"10.3390/cancers17183065","DOIUrl":"10.3390/cancers17183065","url":null,"abstract":"<p><strong>Background/objectives: </strong>The classification and staging of brainstem glioma have its own pitfalls. Surgical biopsy is only possible in a small number of cases. Diagnosis relies mainly on radiological features. Any treatment may have a significant impact on quality of life; therefore, the correct and early identification of potentially malignant lesions is essential to initiate proper therapy. Amino acid PET/CT with accurate metabolic mapping can help in this decision-making.</p><p><strong>Methods: </strong>We performed a retrospective analysis of 20 patients who underwent static FET PET/CT with uncertain brainstem lesions between November 2019 and April 2023. We used multiple tumor-to-brain ratios (TBR) to assess patient subgroups showing long-term and short-term survival.</p><p><strong>Results: </strong>The maximum Youden index was reached at TBR = 2.9. With this ratio, the estimated sensitivity was at the desired level (91.7%), both positive and negative predictive values are in the good performance range (68.8 and 75.0%), while specificity was lower than expected (37.5%).</p><p><strong>Conclusions: </strong>The prognosis of brainstem glioma remains challenging. The use of static FET PET/CT results in more accurate detection of high-grade lesions. In our analysis, we found a TBR value of 2.9 to be the most appropriate for identifying patients with a poor prognosis.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145173815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Restorative Low Anterior Resection Is Associated with Poor Intermediate-Term Oncological Outcomes in MRI-Defined Rectal Cancer. 非恢复性前低位切除术与mri定义的直肠癌中期肿瘤预后差相关。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183074
Ritch T J Geitenbeek, Mark Broekman, Thijs A Burghgraef, Esther C J Consten, Roel Hompes
{"title":"Non-Restorative Low Anterior Resection Is Associated with Poor Intermediate-Term Oncological Outcomes in MRI-Defined Rectal Cancer.","authors":"Ritch T J Geitenbeek, Mark Broekman, Thijs A Burghgraef, Esther C J Consten, Roel Hompes","doi":"10.3390/cancers17183074","DOIUrl":"10.3390/cancers17183074","url":null,"abstract":"<p><strong>Background: </strong>Non-restorative low anterior resection (NRLAR) may result in inferior oncological outcomes compared to restorative low anterior resection (RLAR) and abdominoperineal resection (APR). While NRLAR is often performed when poor functional or technical challenges are anticipated, comprehensive data on its oncological outcomes remain scarce. This study aimed to retrospectively evaluate the intermediate-term oncological outcomes of patients-who underwent RLAR, NRLAR, or APR for primary rectal cancer.</p><p><strong>Methods: </strong>This analysis included all elective NRLAR, RLAR, and APR procedures for primary rectal carcinoma performed across 11 Dutch centers from 2013 to 2020. The primary outcome was 3-year disease-free survival (DFS). Secondary outcomes included 3-year overall survival (OS) and 3-year local recurrence (LR). KaplanMeier survival analysis with log-rank testing and multivariate Cox regression analysis were employed.</p><p><strong>Results: </strong>A total of 253 (12.5%) patients underwent NRLAR, 1109 (55.0%) RLAR, and 656 (32.5%) APR. NRLAR was associated with a lower 3-year DFS (71.4%) versus RLAR (82.0%) and APR (77.4%) (<i>p</i> = 0.003). The 3-year OS was lower for NRLAR (82.9%) versus RLAR (93.5%) and APR (90.2%) (<i>p</i> < 0.001), with a higher 3-year LR rate for NRLAR (8.1%) versus RLAR (3.3%) and APR (4.5%) (<i>p</i> = 0.003). Multivariate Cox regression analyses confirmed NRLAR as an independent predictor for poorer DFS (HR 1.34; 95% CI: 1.01-1.80; <i>p</i> = 0.046), OS (HR 1.57; 95% CI: 1.04-2.36, <i>p</i> = 0.032), and higher LR risk (HR 2.66; 95% CI: 1.53-4.65; <i>p</i> <= 0.001).</p><p><strong>Conclusions: </strong>NRLAR is associated with poorer intermediate-term oncological outcomes. When technically feasible, restorative options should be considered, and prospective studies are required to further investigate causal relationships.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histotripsy: Recent Advances, Clinical Applications, and Future Prospects. 组织切片术:最新进展、临床应用和未来展望。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183072
Mustaqueem Pallumeera, Marcus Hong, Jonathan C Giang, Mina S Makary
{"title":"Histotripsy: Recent Advances, Clinical Applications, and Future Prospects.","authors":"Mustaqueem Pallumeera, Marcus Hong, Jonathan C Giang, Mina S Makary","doi":"10.3390/cancers17183072","DOIUrl":"10.3390/cancers17183072","url":null,"abstract":"<p><p>Histotripsy is a novel, non-invasive ultrasound-based ablative therapy that destroys tissue through focused cavitation. As solid tumors continue to be a major global health burden, there is interest in image-guided ablation techniques that reduce collateral damage and promote immune activation. This narrative review aims to synthesize current advancements, clinical applications, limitations, and future directions of histotripsy in both oncologic and non-oncologic contexts. A comprehensive literature search was conducted from database inception to July 2025. Search terms included combinations of subject headings and keywords such as \"histotripsy,\" \"mechanical ablation,\" \"ultrasound,\" and \"solid tumors.\" Boolean operators and truncation were used to increase sensitivity. Peer-reviewed studies were included, encompassing preclinical, clinical, and review articles. Reference lists of relevant articles were examined to identify additional sources. Histotripsy has shown strong potential in the treatment of tumors involving the liver, pancreas, kidney, brain, and cardiovascular system. It offers real-time imaging guidance, sharp lesion boundaries, and minimal damage to surrounding structures. Early clinical trials have demonstrated encouraging safety and efficacy, particularly in liver and kidney tumors. Its ability to preserve critical anatomy and stimulate innate and adaptive immune responses through the release of cellular debris and cytokines offers advantages over thermal ablation. Limitations include acoustic aberration, motion-related targeting challenges, and the need for further long-term clinical data. Histotripsy represents a promising advancement in noninvasive tumor ablation. Continued clinical investigation and technological refinement are necessary to validate its therapeutic value and define its role within comprehensive cancer care.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145172914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout. 肉瘤细胞治疗的未来方向和重点:来自肉瘤科学细胞治疗突破的战略进展报告。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183068
Jacqueline Oliva-Ramirez, David Milewski, Lauren Banks, Kelly M Bailey, Everett J Moding, Jessica Lake, Alice Chen, Jessica D Daley, Erin E Resch, Rosandra N Kaplan, Brian H Ladle, Lindy Zhang, Margaret M Chou, Rosa Nguyen, Urania Dagalakis, Nourhane Al Akoum, Poul H Sorensen, Jonathan A Fletcher, Ronald DeMatteo, Nicolas J Llosa, Seth M Pollack
{"title":"Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout.","authors":"Jacqueline Oliva-Ramirez, David Milewski, Lauren Banks, Kelly M Bailey, Everett J Moding, Jessica Lake, Alice Chen, Jessica D Daley, Erin E Resch, Rosandra N Kaplan, Brian H Ladle, Lindy Zhang, Margaret M Chou, Rosa Nguyen, Urania Dagalakis, Nourhane Al Akoum, Poul H Sorensen, Jonathan A Fletcher, Ronald DeMatteo, Nicolas J Llosa, Seth M Pollack","doi":"10.3390/cancers17183068","DOIUrl":"10.3390/cancers17183068","url":null,"abstract":"<p><strong>Background: </strong>In September of 2024, the 2nd annual meeting of the Strategic Advances in Sarcoma Science (SASS) convened at the National Institutes of Health. This gathering of national sarcoma experts focused on preclinical studies, clinical trials, opportunities, challenges, and future directions in sarcoma biology and clinical care with a focus on immunotherapy. The Immunology in Sarcoma breakout group conducted a dedicated discussion focused on the current and future implementation of adoptive cellular therapies (ACTs) in sarcomas. The current manuscript summarizes these discussions and provides a comprehensive resource for researchers and clinicians.</p><p><strong>Results: </strong>Adoptive cell therapy (ACT) has shown encouraging results in sarcomas with afami-cel achieving durable responses in synovial sarcoma and early TCR-T trials against NY-ESO-1 and MAGE-A4 demonstrating meaningful response rates. Building on these outcomes will require discovering new targets, selecting optimal cell types, refining conditioning regimens, combining with alternative treatment strategies such as TKIs, and leveraging predictive biomarkers informed by a deeper understanding of the tumor microenvironment.</p><p><strong>Conclusions: </strong>Sarcomas are promising targets for adoptive cell therapy (ACT), as shown by afami-cel's success in synovial sarcoma, but broader impact requires new target discovery, optimal cell selection, improved conditioning, combination treatments, deeper tumor microenvironment understanding, and predictive biomarkers to achieve more durable responses for more patients.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. 肽受体放射性核素治疗(PRRT)使用锕-225和Ac-225/镥-177标记(TANDEM)生长抑制素受体拮抗剂DOTA-LM3治疗神经内分泌肿瘤:一项关于安全性和生存率的回顾性研究。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183070
Elisabetta Perrone, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Kriti Ghai, Aleksandr Eismant, Tanay Parkar, Lukas Greifenstein, Richard Paul Baum
{"title":"Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.","authors":"Elisabetta Perrone, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Kriti Ghai, Aleksandr Eismant, Tanay Parkar, Lukas Greifenstein, Richard Paul Baum","doi":"10.3390/cancers17183070","DOIUrl":"10.3390/cancers17183070","url":null,"abstract":"<p><p>Peptide Receptor Radionuclide Therapy (PRRT) offers radiomolecular precision medicine for somatostatin receptor (SSTR)-positive advanced neuroendocrine neoplasms (NEN). In cases resistant to Lutetium-177-labeled DOTATATE or DOTATOC PRRT, alpha-therapy with Actinium-225 labeled with SSTR antagonists like DOTA-LM3 can be a notable therapeutic option. This retrospective study aimed to assess [<sup>225</sup>Ac]Ac-DOTA-LM3 safety in advanced NEN patients (as monotherapy and with Lutetium-177 as TANDEM), survival, and follow-up duration. Thirty-five patients received a total of 57 [<sup>225</sup>Ac]Ac-DOTA-LM3 cycles (March 2022-September 2024): 24 monotherapies and 33 TANDEM therapies. The pancreas was the most common primary site (<i>n</i> = 19). PRRT-related toxicity was assessed, focusing on hematological, renal, and hepatic toxicity (Common Terminology Criteria for Adverse Events-CTCAE v5.0). Therapy was generally well tolerated, with mostly mild acute adverse events (primarily nausea, <i>n</i> = 8). Some new grade 3/4 long-term adverse events were reported after treatment: anemia grade 3 (<i>n</i> = 2), leukocytopenia grade 4 (<i>n</i> = 1), absolute neutrophil count reduction grade 3 (<i>n</i> = 1), thrombocytopenia grade 3 (<i>n</i> = 7), acute myeloid leukemia (<i>n</i> = 1), nephrotoxicity grade 3 (<i>n</i> = 2), and hepatotoxicity grade 3 (<i>n</i> = 2). During follow-up, 13 patients died (survival range 5-30 months); 22 patients were alive (follow-up range 1-18 months). Our retrospective analysis shows that [<sup>225</sup>Ac]Ac-DOTA-LM3 PRRT is relatively safe concerning acute and long-term toxicity and bears promising survival outcomes in patients progressing after [<sup>177</sup>Lu]Lu-DOTATATE or [<sup>177</sup>Lu]Lu-DOTATOC PRRT.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer. 胆道癌液体活检检测可操作基因组改变的相关因素。
IF 4.4 2区 医学
Cancers Pub Date : 2025-09-19 DOI: 10.3390/cancers17183071
Hiroshi Shimizu, Rei Suzuki, Hiroyuki Asama, Kentaro Sato, Kento Osawa, Rei Ohira, Keisuke Kudo, Mitsuru Sugimoto, Hiromasa Ohira
{"title":"Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer.","authors":"Hiroshi Shimizu, Rei Suzuki, Hiroyuki Asama, Kentaro Sato, Kento Osawa, Rei Ohira, Keisuke Kudo, Mitsuru Sugimoto, Hiromasa Ohira","doi":"10.3390/cancers17183071","DOIUrl":"10.3390/cancers17183071","url":null,"abstract":"<p><p><b>Background</b>: Blood-based comprehensive genomic profiling (CGP), a form of liquid biopsy, is often used for biliary tract cancer (BTC) when tissue-based CGP (tissue CGP) is unavailable, despite lower detection rates. This study explored factors linked to detecting actionable genomic alterations to optimize its use. <b>Methods</b>: We retrospectively analyzed BTC cases in Japan's C-CAT (June 2019-January 2025), restricting panel comparisons to FoundationOne<sup>®</sup> CDx (F1; n = 5019) and FoundationOne<sup>®</sup> Liquid CDx (F1L; n = 1550). Missing covariates were handled by multiple imputations (m = 20). Between-panel balance used 1:1 propensity-score matching (caliper 0.2). Outcomes were modeled with logistic regression. Targets included MSI-H, TMB-H, <i>FGFR2</i>/<i>RET</i>/<i>NTRK</i> fusions, <i>BRAF</i> V600E, <i>KRAS</i> G12C, <i>IDH1</i> mutations, and <i>ERBB2</i> amplification. An exploratory analysis stratified results by the number of prespecified enrichment factors (0-4). Liquid biopsy was performed using plasma-based comprehensive genomic profiling assays (FoundationOne<sup>®</sup> Liquid). <b>Results</b>: Missingness was low; after matching (n = 1549 per group) covariates were well balanced (all|SMD|≤0.05). Detection of any actionable alteration was lower with F1L than F1 (16.8% vs. 24.8%; OR 0.61, 95% CI 0.49-0.75; <i>p</i> < 0.001). F1L also had lower TMB-H (OR 0.62, 0.43-0.90; <i>p</i> = 0.01) and <i>ERBB2</i> amplification (OR 0.42, 0.31-0.57; <i>p</i> < 0.001), with no significant differences for MSI-H, <i>IDH1</i>, <i>KRAS</i> G12C, or <i>BRAF</i> V600E. Within F1L, non-perihilar location (OR 2.05), liver (1.90), lymph-node (1.41), and lung metastases (1.52) predicted detection of actionable genomic alterations. F1L detection increased from 5.8% (zero factors) to 32.8% (four factors), approximating tissue at three factors. <b>Conclusions</b>: The utility of liquid biopsy can be maximized by carefully selecting samples on the basis of conditions that increase the detection rate.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145174036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信